Aptimmune raises capital to accelerate its mucosal vaccine candidates through development and product registration. Aptimmune Biologics raised $2.75 million of series A funding to create new swine vaccines based on advanced mucosal technology. Also, a new CEO joins the company to drive development and commercialization. Dr. Frederico Zuckermann and Aaron Gilbertie will lead the company forward through pipeline development, product registration, and commercialization of the revolutionary vaccines. Aptimmune is an IllinoisVENTURES portfolio company.